Oxford Asset Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Oxford Asset Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-201,746	Closed	-$1.76M	–	1488
2019 Q4	$1.76M	Buy	201,746 +88,498	+78%	+$478K	0.05%	499
2019 Q3	$377K	Sell	113,248 -25,082	-18%	-$100K	0.01%	1369
2019 Q2	$685K	Buy	138,330 +8,541	+7%	+$45.4K	0.01%	1144
2019 Q1	$805K	Buy	129,789 +87,558	+207%	+$423K	0.02%	1035
2018 Q4	$142K	Buy	+42,231	New	+$197K	﹤0.01%	1607
2018 Q1	–	Sell	-73,311	Closed	-$966K	–	1955
2017 Q4	$966K	Buy	73,311 +13,771	+23%	+$202K	0.02%	953
2017 Q3	$927K	Buy	59,540 +6,328	+12%	+$89.5K	0.02%	969
2017 Q2	$747K	Buy	+53,212	New	+$1.14M	0.01%	984

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Oxford Asset Management's JNCE Position: Q1 2020 in Review

Oxford Asset Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2020, closing a stake of 201,746 shares — an estimated $1.76M sold.

Oxford Asset Management first reported a position in JNCE in Q2 2017 and held it in 8 quarters. The position peaked at $1.76M in Q4 2019. 88 funds tracked by Wall St. Rank hold JNCE as of Q1 2020.

Oxford Asset Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 201,746 Jounce Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $1.76M.
Oxford Asset Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2017 and held it in 8 quarters.
Oxford Asset Management's Jounce Therapeutics, Inc. Common Stock position peaked at $1.76M in Q4 2019.
88 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.